US House expands probe on McNeil GMP to "phantom recall" contractors
This article was originally published in Scrip
A congressional oversight committee investigating GMP issues at Johnson & Johnson's McNeil facility in Fort Washington, Pennsylvania, has initiated a new probe. The chairman of the House Committee on Oversight and Government Reform, Edolphus Towns, has asked certain contracting companies whether they were hired by J&J in late 2008 to go into retail stores and secretly purchase suspect tablets of adult Motrin IB 200 (ibuprofen) as part of an alleged plan to remove the product from store shelves without initiating a formal recall.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.